Perioperative Anesthetic and Hormonal Considerations in a Patient With Anti-glutamic Acid Decarboxylase Encephalitis: A Case Report. [PDF]
McArdle IW, Malik H, Dotson S, Kohli A.
europepmc +1 more source
Trastuzumab-associated prurigo nodularis successfully treated with nemolizumab: A case report. [PDF]
Chen R +5 more
europepmc +1 more source
Aprepitant versus Olanzapine in Patients of Breast Cancer on Adriamycin and Cyclophosphamide Regimen - Role in Effectiveness of Prevention of Nausea and Vomiting. [PDF]
Sarma ID +5 more
europepmc +1 more source
Correction to: Comparative effectiveness of netupitant-palonosetron plus dexamethasone versus aprepitant-based regimens in mitigating chemotherapy-induced nausea and vomiting: a meta-analysis of randomized controlled trials. [PDF]
europepmc +1 more source
Fosaprepitant for the prevention of multiple-day cisplatin chemotherapy-induced nausea and vomiting: a prospective randomized controlled study. [PDF]
Wang L +8 more
europepmc +1 more source
Enhanced efficacy of aprepitant-based triple prophylaxis in preventing postoperative nausea and vomiting following metabolic bariatric surgery: a single-center, retrospective cohort study. [PDF]
Shan X +7 more
europepmc +1 more source
Exploring antiemetic strategies in hematologic malignancies: a comprehensive literature review and evaluation of antiemetic efficacy in patients receiving high-dose chemotherapy prior to hematopoietic stem cell transplantation. [PDF]
Jordan K, Jordan B, Burgt JV, Jahn F.
europepmc +1 more source
Comparative effectiveness of netupitant-palonosetron plus dexamethasone versus aprepitant-based regimens in mitigating chemotherapy-induced nausea and vomiting: a meta-analysis of randomized controlled trials. [PDF]
Luo WT, Chang CL, Huang TW, Gautama MSN.
europepmc +1 more source
Evaluating the potential to predict chemotherapy-induced nausea and vomiting in carboplatin-containing treatment based on symptoms induced by prior cisplatin-containing treatment. [PDF]
Saito Y +6 more
europepmc +1 more source
Impact of antiemetic prophylaxis on reducing trastuzumab deruxtecan dose modifications in HER2+/HER2-low breast cancer. [PDF]
Shin J, Kim JY, Ahn HK, Ahn JS, Park YH.
europepmc +1 more source

